PTC Therapeutics/$PTCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Ticker
$PTCT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
939
ISIN
US69366J2006
Website
PTC Therapeutics Metrics
BasicAdvanced
$3.9B
6.61
$7.51
0.52
-
Price and volume
Market cap
$3.9B
Beta
0.52
52-week high
$58.38
52-week low
$28.72
Average daily volume
1.1M
Financial strength
Current ratio
157.966
Quick ratio
157.966
Long term debt to equity
-1,196.881
Total debt to equity
-1,283.471
Interest coverage (TTM)
4.80%
Profitability
EBITDA (TTM)
895.797
Gross margin (TTM)
67.12%
Net profit margin (TTM)
33.55%
Operating margin (TTM)
48.98%
Effective tax rate (TTM)
8.68%
Revenue per employee (TTM)
$1,890,000
Management effectiveness
Return on assets (TTM)
24.42%
Return on equity (TTM)
-110.19%
Valuation
Price to earnings (TTM)
6.606
Price to revenue (TTM)
2.162
Price to book
-21.16
Price to tangible book (TTM)
-21.16
Price to free cash flow (TTM)
5.643
Free cash flow yield (TTM)
17.72%
Free cash flow per share (TTM)
879.25%
Growth
Revenue change (TTM)
91.12%
Earnings per share change (TTM)
-197.92%
3-year revenue growth (CAGR)
46.02%
10-year revenue growth (CAGR)
54.08%
3-year earnings per share growth (CAGR)
0.59%
10-year earnings per share growth (CAGR)
7.97%
What the Analysts think about PTC Therapeutics
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Bulls say / Bears say
PTC Therapeutics reported $814 million in 2024 revenue, surpassing its guidance, driven by strong sales from its Duchenne Muscular Dystrophy franchise, including Translarna™ and Emflaza® (Investing.com).
The company secured a significant collaboration with Novartis for its PTC518 program, receiving a $1.0 billion upfront payment and potential for up to $1.9 billion in future milestones, enhancing its financial position (Investing.com).
PTC Therapeutics received a positive CHMP opinion for Sephience™ (sepiapterin) for the treatment of Phenylketonuria (PKU), with European launch preparations underway, indicating potential for new revenue streams (PTC Therapeutics Press Release).
The expiration of Emflaza's orphan drug exclusivity in February 2024 led to a decline in net product revenues to $207.2 million for full year 2024, down from $255.1 million in 2023, potentially impacting future revenue (SEC Filing).
PTC Therapeutics reported a net loss of $363.3 million for full year 2024, compared to a net loss of $626.6 million in 2023, indicating ongoing financial challenges despite revenue growth (SEC Filing).
The European Commission adopted the CHMP's opinion to not renew the authorization of Translarna™ (ataluren) in Europe, potentially affecting the company's revenue from this product (PTC Therapeutics Press Release).
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
PTC Therapeutics Financial Performance
Revenues and expenses
PTC Therapeutics Earnings Performance
Company profitability
PTC Therapeutics News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
GlobeNewsWire·1 week ago
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $3.9B as of June 26, 2025.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 6.61 as of June 26, 2025.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.